Extended Executive Management

Marija Stanisavljević is a distinguished economist with a solid foundation in administration and leadership across diverse business sectors.

Dr. Frugier is an experienced patent manager and a qualified European Patent Attorney with a focus on supporting small to mid-sized biotech entities in protecting and securing access to intellectual property assets critical to their competitiveness and fundraising.

Dr. Patrick Schnider has worked in pharmaceutical research and development as a medicinal chemist and team leader for more than 25 years. He is the inventor and co-inventor of seven drugs that entered clinical development, including the marketed neurokinin 1 receptor antagonist netupitant for the prevention of chemotherapy-induced nausea and vomiting.

Dr. Aurélie Jenn, Head of Regulatory Affairs and Quality Assurance, is a pharmacist (Pharm. D) bringing over 20 years of experience in the pharmaceutical industry. In a first part of her career, she worked in Regulatory Affairs / CMC writing for generic products and New Chemical Entities in Switzerland and France, having close interactions and providing support to technical departments.

Dr. Janet Dawson has a substantial academic and professional background in research and drug development, with expertise spanning areas of pharmacology, inflammation, rheumatology, and various experimental techniques.

Dr. Paul Hebeisen is a highly experienced medicinal chemist with an impressive track record in drug discovery over 28 years of service at F. Hoffmann-La Roche AG, Switzerland. Paul served in various positions, most notably as a Group Leader in Chemistry in the discovery of novel anti-infectives.

Dr. Christoph Heusser, Head of Immunology, is an immunology expert who pioneered antibody-based therapies and antibody-mediated effector functions. He was Head of Immunology at Ciba-Geigy and Head of the Transplantation- Immunology Unit at Novartis and gave lectures on antibody-based interventions at the University Basel for 15 years.

Dr. Robert Ettlin is the Head of Preclinical Safety in Swiss Rockets. After some years in toxicological pathology at F. Hoffmann La Roche Ltd., Ettlin joined Sandoz Ltd. in Basel, where he advanced to Head of Toxicology and later Head of Development Operations Switzerland.

Michel Petignat, Head of Human Resources, is a qualified HR Specialist in the Life Sciences industry. During his long and outstanding professional career, Michel worked as an HR Manager in leading pharma and biotech companies such as Sandoz, Novartis Pharma, Syngenta Crop Protection and Actelion Pharmaceuticals.

Dr. Bernhard Hostettler, Head of Intellectual Property, originally is an organic chemist. After his Ph.D. at ETH Zürich, Bernhard was active in research for more than 20 years with companies Roche, CIBA, Syngenta and Givaudan.

Beat Ritschard is a skilled senior executive with over 35 years of experience in the pharma and biotech industry. He has recently joined Swiss Rockets as Head of Financial Planning & Controlling, where he will oversee budgeting, controlling, planning and other strategic projects.

Maciej Talarek, Financial Advisor, started his career in the insurance industry. As a result, he specialized in accounting and found his future in the fiduciary sector.

Albert Muntane Casanova is an accomplished manager responsible for overseeing the financial activities of the company.

Richard Hubler holds multiple degrees, showcasing a diverse and accomplished academic background. He is a Germanist and Historian, and also holds a degree in Law.